Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. “We are very pleased with the rapid completion of enrollment achieved by the team at the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands,” said Alexandra Mancini, InMed’s Senior Vice President of Clinical Development & Regulatory Affairs.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

JUNE 1, 2021

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. Los Angeles, California. www.InvestorBrandNetwork.com.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

Veriheal

APRIL 11, 2022

The final goal is to introduce medicinal cannabis products to the pharmaceutical drug market. This means that the medical and scientific communities can now celebrate broader access to research for the production of pharmaceutical products that are safer than smokable or vaporizable cannabis. Drug Enforcement Agency (DEA). federal law.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Cannabis Law Report

AUGUST 17, 2021

.–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. Ganaxolone was generally well-tolerated with somnolence reported as the most common adverse event, consistent with previous trials; in addition, one treatment-related serious adverse event of seizure was reported in the trial.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. Flora Pharma expects to fast track traditional FDA and NHS timelines by running phase trials in parallel (in vitro, in vivo, pilot in human, safety/efficacy, etc.).

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Cannabis Law Report

JULY 7, 2021

Company plans to initiate Phase II trial with a leading academic institution. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. The BioMAP Diversity PLUS Panel provides biologically relevant in vitro models of human disease and is used to analyze drug candidate compounds, from discovery to preclinical safety.

Pharmaceutical 105

Pharmaceutical Data Clinical Trials Research and Development 105

Cannabis Law Report

DECEMBER 3, 2021

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. Chief Executive Officer of Marinus Pharmaceuticals. “We Chief Executive Officer of Marinus Pharmaceuticals. “We Ganaxolone was generally well-tolerated and no new safety findings emerged in the LGS subgroup. RADNOR, Pa.–(BUSINESS

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Cannabis Law Report

OCTOBER 26, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that Chris Chapman, M.D., Chapman has operated Chapman Pharmaceutical Consulting, Inc., MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. The secondary measures will be the safety, tolerability, and pharmacokinetics in this population of patients. About MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

AUGUST 5, 2021

Additionally, the technology backed by the patent will be essential for transforming variable psychedelic raw materials into pharmaceutical-grade standardized extracts. This approval represents important progress in the development of our intellectual property,” Benjamin Lightburn, CEO of Filament, said in a press release. “At

Extraction 105

Extraction Clinical Trials Research and Development Pharmaceutical 105

Cannabis Law Report

JULY 28, 2021

This includes First Time in Human (“FTiH”) clinical trials, which are expected to commence in 2022, for the Group’s lead compound OCT461201, a selective cannabinoid receptor type 2 (“CB2”) agonist with initial indications in the areas of post herpetic neuralgia and visceral pain caused by irritable bowel syndrome.

Cannabinoids 105

Cannabinoids Clinical Trials Safety Medicine 105

MMJ Recs

APRIL 1, 2024

Furthermore, ongoing clinical trials are investigating CBD’s efficacy in treating conditions such as multiple sclerosis, Parkinson’s disease, and substance abuse disorders. By promoting relaxation and reducing anxiety, CBD may help individuals achieve restful sleep without the need for pharmaceutical interventions.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

JUNE 17, 2021

This landmark investment and strategic transaction solidifies Brains’ position as one of the leading pharmaceutical companies in the cannabinoid (CBD) sector. To have the confidence of DSM in this next round solidifies Brains strategic position within the pharmaceutical industry,” said Brains’ CEO & Chairman Rick Brar.

Pharmaceutical 105

Pharmaceutical Clinical Trials Research and Development Events 105

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Enquiries: GW Pharmaceuticals plc.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Canna Law Blog

NOVEMBER 15, 2021

With ketamine as the only psychedelic treatment that can (currently) be legally prescribed and administered “off label” by licensed physicians, many entrants into the psychedelic space have started with operating ketamine clinics, with the goal of expanding to other psychedelic treatments when legally permissible.

Clinical Trials 98

Clinical Trials Treatment Microdosing Pharmaceutical 98

Cannabis Law Report

JUNE 21, 2021

Algernon Pharmaceuticals Inc. OTC: EHVVF) adds Dr. Jeffrey Kamlet, an expert on cardiac safety in ibogaine treatment, as Chief Medical Officer. retains CRO Sante Cannabis to conduct clinical trials in psilocybin therapies. (CSE: ENBI). 0.0395 -0.125 (-24.04%). 0.135 -0.025 (-15.62%). Red Light Holland Corp. CSE: TRIP).

Clinical Trials 66

Clinical Trials Research and Development Therapy Pharmaceutical 66

Canna Care Docs

OCTOBER 3, 2023

However, many of these pharmaceutical medications can just induce more unpleasant, debilitating effects on those who are ill. Depending on the type of terminal illness diagnosed by the doctor, there are numerous pharmaceutical and conventional medications provided for patients to treat the symptoms that come with a terminal illness.

Chronic Pain 105

Chronic Pain Clinical Trials Patients Cannabinoids 105

Cannabis Law Report

APRIL 21, 2022

The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use following anticipated regulatory approvals. in each of the four validation trials with an acceptable yield, which is a noteworthy accomplishment.

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

Cannabis Law Report

NOVEMBER 22, 2019

“As MMJ International Holdings continues to advance to its clinical trials, a specialty pharmaceutical solutions company will be supporting MMJ with the FDA, DEA required development API and specialized liquid encapsulation solutions,” said Elio Mariani, PhD, EVP of Research & Development.

DEA 66

DEA Clinical Trials THC Research and Development 66

The Cannigma

MARCH 7, 2022

What can the current clinical trials tell us? A common theme with cannabis is that more research is needed, so thankfully there are clinical trials in the works looking at the therapeutic utility of CBN. Those recruited will apply either CBN cream or placebo to non-wounded areas over a course of 28 days.

THC 140

THC Sleep Clinical Trials Cannabinoids 140

Cannabis Law Report

JULY 24, 2021

The groundbreaking progress that we’ve seen from the Multidisciplinary Association for Psychedelic Studies (MAPS) in its Phase 3 clinical trials of MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder (PTSD), including receiving Breakthrough Therapy Designation from the Food and Drug Administration (FDA), shows great promise to date.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

Cannabis Law Report

JUNE 21, 2021

Pharmaceutical companies use artificial intelligence (AI) to sort through reams of scientific data to find potentially effective active ingredients to be developed into approved drugs. Taking the doctor-patient use of RYAH devices one step further, organizations conducting clinical trials are finding value in the company’s offerings.

Data 105

Data Clinical Trials Research and Development Indica 105

Cannabis Law Report

JUNE 15, 2021

This landmark investment and strategic transaction solidifies Brains’ position as one of the leading pharmaceutical companies in the cannabinoid (CBD) sector. To have the confidence of DSM in this next round solidifies Brains strategic position within the pharmaceutical industry,” said Brains’ CEO & Chairman Rick Brar.

Pharmaceutical 82

Pharmaceutical Clinical Trials Research and Development Events 82

Cannabis Law Report

MARCH 1, 2022

Focus will be on IND/CTA filings and associated interactions, and may include safety reports, protocols, information amendments, responses to requests for information, IND Annual Reports/DSURs, and new investigator amendments. 10 years of experience in the pharmaceutical industry. +5 5 years of hands-on regulatory experience.

Clinical Trials 52

Clinical Trials Environment Pharmaceutical Programs 52

Cannabis Law Report

SEPTEMBER 12, 2022

Our mushrooms are some of the most tested products on the planet as we cross the lines between Pharmaceutical, Agriculture, Botanical, and Food testing quality assays,” said Optimi Chief Science Officer, Justin Kirkland. The harvest includes the following psilocybin-containing mushroom strains: Koh Samui. Penis Envy. Blue Pulaski.

History 52

History Clinical Trials Legalization Research and Development 52

Cannabis Law Report

JANUARY 24, 2022

Accomplished leader to oversee Goldfinch Bio’s clinical function to advance precision medicines for people living with kidney disease. Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. CAMBRIDGE, Mass.–(BUSINESS

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

Cannabis Law Report

AUGUST 23, 2021

At the end of the programme, Evotec will provide the Company with a submission-ready regulatory document which will be used for submissions to regulatory agencies, as well as drug-batch approved and ready for First Time in Human clinical trials. . & Notice of 2021 Final Results. . Since the year-end, the £2.6

Cannabinoids 98

Cannabinoids Research and Development Clinical Trials Packaging 98

Cannabis Law Report

OCTOBER 2, 2021

Focus will be on IND/CTA filings and associated interactions, and may include safety reports, protocols, information amendments, responses to requests for information, IND Annual Reports/DSURs, and new investigator amendments. 10 years of experience in the pharmaceutical industry. +5 5 years of hands-on regulatory experience.

Clinical Trials 52

Clinical Trials Environment Pharmaceutical Programs 52

Cannabis Law Report

SEPTEMBER 20, 2021

The products leverage pharmaceutical technology to maximize performance and safety. Additional CB4 products from the Opticann suite of branded products will be launched in the upcoming weeks, including CB4 Derma skin cream and CB4 Clear face gel skincare products uniquely backed by product specific clinical trial data.

Clinical Trials 52

Clinical Trials Pharmaceutical Data Patients 52

Cannabis Law Report

JUNE 25, 2021

Major players in the global skin cancer drugs market are Novartis AG, Bristol Myers Squibb, Eli Lilly, Meda, and Sun Pharmaceutical Industries Ltd. The European Medicines Agency (EMA) is the regulatory body that evaluates and supervises the production and sales of medicines for safety and benefit of the customer, in the European Union Region.

Research and Development 84

Research and Development Therapy Pharmaceutical Clinical Trials 84

Veriheal

JANUARY 5, 2023

A randomized, double-blind, cross-over trial of cannabis recently published by Research Gate explored whether or not cannabidiol (CBD) — the primary non-intoxicating constituent of cannabis and hemp — improves or reduces the cannabis safety. . About the Study Into CBD’s Influence on Cannabis Safety.

Clinical Trials 96

Clinical Trials Safety Consumption CBD 96

Cannabis Law Report

JULY 1, 2021

Clinical trials repeatedly demonstrate their promise for treating mood, anxiety, and substance use disorders. POPLAR will focus on promoting safety, innovation, and equity in psychedelics research, commerce, and therapeutics. Background. The Project. It is supported by a generous grant from the Saisei Foundation.

Law 59

Law Policy Research and Development Clinical Trials 59

MedicalJane

MAY 21, 2020

Researchers at The University of New Mexico (UNM) have conducted a series of recent studies testing the effectiveness and safety of consuming cannabis, but this is the first study they have conducted measuring the therapeutic potential of hemp oil with low THC levels.

Oil 100

Oil Hemp Extraction Clinical Trials 100

Cannabis Law Report

FEBRUARY 15, 2019

The Singapore Online Citizen reports… Law & Home Affairs Minister K Shanmugam says that pharmaceutical companies are hiding their intentions behind a smokescreen when it comes to cannabis. These can be administered through pharmaceutical products such as oral solutions and sprays.

Medicine 45

Medicine Pharmaceutical Law Cannabinoids 45

Cannabis Law Report

DECEMBER 5, 2021

MAPS is currently sponsoring the final of two FDA-required Phase 3 trials of MDMA-assisted therapy for PTSD following the successful completion of the first Phase 3 trial and peer-reviewed publication of results in Nature Medicine earlier this year. Interested prospective funders can submit their contact information here.

Therapy 52

Therapy Access Research and Development Clinical Trials 52

Cannabis Law Report

NOVEMBER 9, 2021

As an institution dedicated to diagnosing and treating serious blood diseases and with the ability to pursue investigational medicines from development to manufacture and clinical trial for patients who have exhausted all approved treatment options, having a cost-effective and rapid production chain is integral to ÚHKT’s mission.

Clinical Trials 52

Clinical Trials Research and Development Therapy Supply Chain 52